Fig. 1 · Structure

Documents & Downloads

Gabapentin

Cat. No. A10413 CAS 60142-96-3
Gabapentin (Neurontin) is a pharmaceutical agent, specifically a GABA analogue.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

In recombinant calcium-channel systems, chronic gabapentin exposure reduced currents through an α2δ-dependent response; binding-site mutants were insensitive. Reduced cell-surface channel-subunit abundance supports a trafficking-related action in these models. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
GABA receptor

Cellular Effect

Cell Line Activity Value Description Reference
CHO IC50 30 μM Inhibition of [3H]leucine uptake into CHO cells by L-amino acid transporters [PMID: 15801823]

In Vitro Studies

The response depends on experimental context. Chronic exposure reduced currents in tsA-201 cells, whereas acute exposure did not. In cultured hippocampal neurons, another study reported no impairment of channel trafficking to boutons after seven days of gabapentin exposure. [1,2]

Chronic versus acute calcium-channel current responses

Cell-based study · tsA-201 cells expressing CaV2.1/β4/α2δ-2; binding-site mutant controls R282A-α2δ-2 and CaV2.2/β1b/R217A-α2δ-1. [1]

Chronic gabapentin reduced wild-type channel currents, whereas acute exposure did not. Corresponding binding-site mutants were insensitive to chronic gabapentin. These controls support an α2δ-dependent response in this expression system; they do not establish a universal acute channel-blocking action.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Reduction of peak IBa at +15 mV relative to matched controlCurrent-density inhibition 72.2 ± 4.2% (mean ± SEM); GBP n=11 cells; control n=13 cells; P=0.0013[1]
Reduction of peak IBa at +15 mV relative to matched controlCurrent-density inhibition 45.0 ± 9.9% (mean ± SEM); GBP n=10 cells; control n=14 cells; P=0.0215[1]
Peak current after acute GBP as percentage of its initial valueCurrent remaining 99.0 ± 7.1% (mean ± SEM); n=5 cells[1]
Response of binding-site mutant channel combinations to chronic GBPQualitative specificity control No inhibition reported; R282A-α2δ-2: GBP n=12, control n=12; R217A-α2δ-1: GBP n=5, control n=4[1]

Literature-Reported Treatment Conditions

Treatment concentration
100 μM or 1 mM
Exposure duration
Approximately 40 h after transfection for chronic exposure; 10 min for acute 1 mM exposure.
Method
Added to culture medium; barium current measured electrophysiologically.
Vehicle
Equivalent H2O control.
Co-treatment
No combination therapy; channel subunits coexpressed.
Reported limits
Detailed culture and recording solutions reside in SI Methods, which was not retrieved; drug supplier/form characterization not recovered from main text.
Methods and source locations

Compound reported in the paper: Gabapentin; Compound label in the paper: GBP

Published gabapentin research; does not validate an Adooq lot, purity, formulation or supplier.

Results: Inhibition of CaV2.1 and CaV2.2 Currents; Prevention by Mutation; Figs 1A,C–E and 2A,C; Statistical Analysis

Reduction of peak IBa at +15 mV relative to matched control: 1 mM GBP for approximately 40 h; Student’s two-tailed t test. — Results first subsection; Fig 1A and caption; Statistical Analysis

Reduction of peak IBa at +15 mV relative to matched control: 100 μM GBP for approximately 40 h; Student’s two-tailed t test. — Results first subsection; Fig 1D–E and caption; Statistical Analysis

Peak current after acute GBP as percentage of its initial value: 1 mM GBP for 10 min; paired temporal comparison; authors report no effect. — Fig 1C caption; Statistical Analysis

Response of binding-site mutant channel combinations to chronic GBP: 1 mM GBP for approximately 40 h; matched H2O controls. No binding-affinity value inferred. — Results: Prevention of the Effect of Chronic GBP; Fig 2A,C captions

Cell-surface channel-subunit localization after chronic exposure

Cell-based study · COS-7 cells expressing CaV2.1–2HA/β4/α2δ-2 (imaging); transfected-cell surface α2δ-2 assessed by biotinylation. [1]

Chronic exposure reduced immunostained surface CaV2.1 and α2δ-2. Orthogonal biotinylation detected a smaller surface fraction of α2δ-2, with intracellular Akt and nonbiotinylated cells serving as controls. The readouts support altered surface abundance, without establishing a specific recycling pathway.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cell-surface fluorescence per cell area for CaV2.1 and α2δ-2Surface fluorescence Reduced at 100 μM and 1 mM; control n=22 cells, 100 μM n=19, 1 mM n=24; images representative of three independent experiments[1]
Reduction in surface α2δ-2 fraction, normalized to whole-cell α2δ-2Surface-fraction reduction 19.8 ± 7.6% at 100 μM; 30.4 ± 14.4% at 1 mM (mean ± SEM); n=5 experiments; P<0.05[1]

Literature-Reported Treatment Conditions

Treatment concentration
100 μM or 1 mM
Exposure duration
Imaging: 48 h culture with GBP; biotinylation: performed 72 h after transfection, with GBP exposure duration not explicitly specified in main text.
Method
Culture exposure; nonpermeabilized immunostaining and cell-surface biotinylation/immunoblotting.
Vehicle
Control without GBP; H2O used as vehicle in current experiments, but imaging vehicle not separately specified.
Co-treatment
No combination therapy.
Reported limits
SI Methods not retrieved. Biotinylation GBP incubation duration and drug supplier not recovered; do not transfer the 48 h imaging interval to this assay.
Methods and source locations

Compound reported in the paper: Gabapentin; Compound label in the paper: GBP

Published gabapentin research; does not validate an Adooq lot, purity, formulation or supplier.

Results: Chronic GBP Reduces Plasma Membrane Expression; Fig 3A–D; Methods: Biotinylation Assay and Statistical Analysis

Cell-surface fluorescence per cell area for CaV2.1 and α2δ-2: Nonpermeabilized imaging after 48 h. No signal in nontransfected cells or without primary antibodies (authors’ data not shown). No fluorescence means inferred from bars. — Fig 3A–C captions; Results: Chronic GBP Reduces Plasma Membrane Expression

Reduction in surface α2δ-2 fraction, normalized to whole-cell α2δ-2: Biotinylation/streptavidin pull-down; repeated-measures ANOVA with Bonferroni post hoc test. Akt absent from biotinylated fraction supports membrane integrity. — Fig 3D caption; Methods: Biotinylation Assay and Statistical Analysis

Reported lack of trafficking impairment in hippocampal neurons

Cell-based study · Cultured rat hippocampal CA3–CA1 neurons transfected with eGFP-α1A; presynaptic boutons identified using synapsin staining. [2]

The authors reported no impairment of channel trafficking to boutons with gabapentin. This limits extrapolation of the heterologous-cell trafficking response to all neuronal contexts. Figure S9’s caption and bar ordering disagree on assignment of the two fluorescence means; neither mean nor a numerical effect size is adopted.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
De novo channel trafficking to synaptic boutons after chronic GBPReported trafficking outcome No impairment reported (qualitative); n=6 as reported[2]

Literature-Reported Treatment Conditions

Treatment concentration
1 mM
Exposure duration
7 days (168 h), from transfection at DIV7 to fixation at DIV14.
Method
GBP in incubation medium; confocal GFP and synapsin immunofluorescence.
Vehicle
Without GBP control; vehicle not specified in selected locations.
Co-treatment
No combination therapy.
Reported limits
Drug supplier and vehicle not specified in selected locations. Fig S9 group-mean assignment unresolved; no p value stated in S9 caption. n=6 is retained as reported, without inferring neurons/dishes.
Methods and source locations

Compound reported in the paper: Gabapentin; Compound label in the paper: GBP

Published gabapentin research; does not validate an Adooq lot, purity, formulation or supplier.

Main gabapentin Results paragraph and Methods; official Supplementary Information p5, Fig S9

De novo channel trafficking to synaptic boutons after chronic GBP: eGFP-α1A fluorescence at synapsin-positive boutons with versus without 1 mM GBP for 7 days. No equivalence test or numeric group assignment claimed. — Official SI p5 Fig S9 title/caption and images/graph; main gabapentin Results paragraph

In Vivo Studies

In rats with paclitaxel-induced neuropathy, repeated gabapentin dosing partially reduced mechanical hypersensitivity, with no effect after the first injection and no persistence at 24 hours. Separate cohorts showed normalization of elevated spinal α2δ-1 after three injections, while DRG levels did not significantly change. These preclinical associations do not establish clinical benefit or a causal link between protein expression and analgesia. [3]

Repeated dosing and mechanical hypersensitivity in paclitaxel neuropathy

Animal study · Adult male Sprague–Dawley rats with established paclitaxel-evoked mechanical hypersensitivity. [3]

Gabapentin partially reduced mechanical hypersensitivity after repeated dosing, with no initial-dose effect and no persistence at 24 h. A separate matched motor-control cohort showed unchanged roto-rod performance (authors’ data not shown; n=8/group).

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Anti-allodynia/anti-hyperalgesia relative to vehicle and naïve baselineBehavioral reversal range 34%–59% across significant responses; n=12/group[3]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Once daily
Treatment course
Four consecutive daily injections; post-paclitaxel baseline D26; treatment began the following day according to Fig 3 caption.
Vehicle
Saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Repeated gabapentin in paclitaxel neuropathy
100 mg/kg
Saline-injected neuropathic rats; n=12/group. Pre-chemotherapy and pre-gabapentin baselines.First injection ineffective; 8 g/15 g responses reduced after injections 2–4 and 4 g responses after injections 3–4 at 1 h. No effect persisted to 24 h.[3]
Repeated gabapentin in paclitaxel neuropathy
Model: Adult male Sprague–Dawley rats with established paclitaxel-evoked mechanical hypersensitivity.
Reported limits: Gabapentin supplier and salt designation not identified in retrieved main text; no Adooq attribution.
Methods and source locations

Compound reported in the paper: Gabapentin; Compound label in the paper: gabapentin

Published gabapentin research; does not validate an Adooq lot, purity, formulation or supplier.

Experimental Procedures: Animals, Behavioral testing, Drug administration, Roto-rod testing, Statistics; Fig 3 and corresponding Results

Anti-allodynia/anti-hyperalgesia relative to vehicle and naïve baseline: von Frey 4 g, 8 g and 15 g withdrawal responses at 1 h and 24 h after each injection; Bonferroni-corrected unpaired t tests. Percent reversal = (vehicle−GBP)/(vehicle−naïve baseline) ×100; this is not a direct percentage reduction in raw withdrawals. — Results: Effects of gabapentin in paclitaxel-treated rats; Fig 3; Statistics

Repeated gabapentin in paclitaxel neuropathy · Experimental Procedures: Drug administration, Behavioral testing; Fig 3; Results: Effects in paclitaxel-treated rats

Spinal and DRG α2δ-1 expression in separate paclitaxel cohorts

Animal study · Adult male Sprague–Dawley rats with established paclitaxel-evoked mechanical hypersensitivity. Additional cohorts distinct from the four-day behavior experiment. [3]

After the first injection, dorsal spinal-cord α2δ-1 remained elevated with either saline or gabapentin. After three gabapentin injections the elevation was normalized; DRG levels did not significantly change. The association with behavioral improvement does not prove that expression normalization causes analgesia.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
α2δ-1 protein relative to naïve controls in DRG and dorsal spinal cordGAPDH-normalized protein expression Dorsal spinal elevation persisted after first injection; normalized after third GBP injection; no significant DRG change; n=7/group[3]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Once daily
Treatment course
Separate cohorts sampled 1 h after first or third daily injection.
Vehicle
Saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Gabapentin and α2δ-1 expression
100 mg/kg
Neuropathic saline groups sampled after first/third injection and naïve rats; n=7/group.Elevated dorsal spinal-cord α2δ-1 returned to the naïve range after three injections; no significant DRG change.[3]
Gabapentin and α2δ-1 expression
Model: Adult male Sprague–Dawley rats with established paclitaxel-evoked mechanical hypersensitivity.
Reported limits: Gabapentin supplier and salt designation not identified in retrieved main text; no Adooq attribution.
Methods and source locations

Compound reported in the paper: Gabapentin; Compound label in the paper: gabapentin

Published gabapentin research; does not validate an Adooq lot, purity, formulation or supplier.

Experimental Procedures: Quantification of α2δ-1 levels, Western blot analysis, Statistics; Results: Effects on α2δ-1 expression; Fig 4A–B

α2δ-1 protein relative to naïve controls in DRG and dorsal spinal cord: Reducing Western blot detects α2 peptide; GAPDH loading control, rat-brain positive control. Fig 4 marks P<0.05 versus naïve, third saline, or first GBP as applicable; no exact band means inferred. — Fig 4A–B and caption; Results: Effects on α2δ-1 expression; Western blot analysis

Gabapentin and α2δ-1 expression · Experimental Procedures: Quantification of α2δ-1 levels, Western blot analysis; Fig 4

Specifications

Manufacturer Adooq Bioscience
CAS Number 60142-96-3
Formula C9H17NO2
Molecular Weight 171.24
Synonyms Neurontin
SMILES
C1CCC(CC1)(CC(=O)O)CN

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Insoluble
Water 31 mg/mL (181.03 mM)
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Jan Hendrich, Alexandra Tran Van Minh, Fay Heblich, et al. Pharmacological disruption of calcium channel trafficking by the α2δ ligand gabapentin Proceedings of the National Academy of Sciences of the United States of America (2008). PMID: 18299583 DOI: 10.1073/pnas.0708930105 Source material
  2. [2] Michael B Hoppa, Beatrice Lana, Wojciech Margas, et al. alpha2delta expression sets presynaptic calcium channel abundance and release probability Nature (2012). PMID: 22678293 DOI: 10.1038/nature11033 Source material
  3. [3] W XIAO, A BOROUJERDI, G J BENNETT, et al. CHEMOTHERAPY-EVOKED PAINFUL PERIPHERAL NEUROPATHY: ANALGESIC EFFECTS OF GABAPENTIN AND EFFECTS ON EXPRESSION OF THE ALPHA-2-DELTA TYPE-1 CALCIUM CHANNEL SUBUNIT Neuroscience (2007). PMID: 17084535 DOI: 10.1016/j.neuroscience.2006.09.044 Source material

Added to your cart

View Cart Checkout
Loading...